1 序文
2 範囲および方法論
2.1 本調査の目的
2.2 利害関係者
2.3 データソース
2.3.1 一次情報源
2.3.2 二次情報源
2.4 市場推定
2.4.1 ボトムアップアプローチ
2.4.2 トップダウンアプローチ
2.5 予測方法論
3 エグゼクティブサマリー
4 はじめに
4.1 概要
4.2 主要産業動向
5 世界の高リン血症治療薬市場
5.1 市場概要
5.2 市場実績
5.3 COVID-19 の影響
5.4 市場予測
6 製品別市場内訳
6.1 セベラマー
6.1.1 市場動向
6.1.2 市場予測
6.2 カルシウム系リン結合剤
6.2.1 市場動向
6.2.2 市場予測
6.3 鉄系リン酸結合剤
6.3.1 市場動向
6.3.2 市場予測
6.4 炭酸ランタン
6.4.1 市場動向
6.4.2 市場予測
6.5 その他
6.5.1 市場動向
6.5.2 市場予測
7 剤型別市場
7.1 錠剤
7.1.1 市場動向
7.1.2 市場予測
7.2 シロップ
7.2.1 市場動向
7.2.2 市場予測
7.3 カプセル
7.3.1 市場動向
7.3.2 市場予測
8 流通チャネル別市場
8.1 病院薬局
8.1.1 市場動向
8.1.2 市場予測
8.2 薬局
8.2.1 市場動向
8.2.2 市場予測
8.3 オンライン薬局
8.3.1 市場動向
8.3.2 市場予測
9 地域別市場
9.1 北米
9.1.1 米国
9.1.1.1 市場動向
9.1.1.2 市場予測
9.1.2 カナダ
9.1.2.1 市場動向
9.1.2.2 市場予測
9.2 アジア太平洋地域
9.2.1 中国
9.2.1.1 市場動向
9.2.1.2 市場予測
9.2.2 日本
9.2.2.1 市場動向
9.2.2.2 市場予測
9.2.3 インド
9.2.3.1 市場動向
9.2.3.2 市場予測
9.2.4 韓国
9.2.4.1 市場動向
9.2.4.2 市場予測
9.2.5 オーストラリア
9.2.5.1 市場動向
9.2.5.2 市場予測
9.2.6 インドネシア
9.2.6.1 市場動向
9.2.6.2 市場予測
9.2.7 その他
9.2.7.1 市場動向
9.2.7.2 市場予測
9.3 欧州
9.3.1 ドイツ
9.3.1.1 市場動向
9.3.1.2 市場予測
9.3.2 フランス
9.3.2.1 市場動向
9.3.2.2 市場予測
9.3.3 英国
9.3.3.1 市場動向
9.3.3.2 市場予測
9.3.4 イタリア
9.3.4.1 市場動向
9.3.4.2 市場予測
9.3.5 スペイン
9.3.5.1 市場動向
9.3.5.2 市場予測
9.3.6 ロシア
9.3.6.1 市場動向
9.3.6.2 市場予測
9.3.7 その他
9.3.7.1 市場動向
9.3.7.2 市場予測
9.4 ラテンアメリカ
9.4.1 ブラジル
9.4.1.1 市場動向
9.4.1.2 市場予測
9.4.2 メキシコ
9.4.2.1 市場動向
9.4.2.2 市場予測
9.4.3 その他
9.4.3.1 市場動向
9.4.3.2 市場予測
9.5 中東およびアフリカ
9.5.1 市場動向
9.5.2 国別の市場内訳
9.5.3 市場予測
10 推進要因、阻害要因、機会
10.1 概要
10.2 推進要因
10.3 阻害要因
10.4 機会
11 バリューチェーン分析
12 ポーターのファイブフォース分析
12.1 概要
12.2 買い手の交渉力
12.3 サプライヤーの交渉力
12.4 競争の度合い
12.5 新規参入の脅威
12.6 代替品の脅威
13 価格分析
14 競合状況
14.1 市場構造
14.2 主要企業
14.3 主要企業のプロフィール
Ardelyx Inc
Fresenius Medical Care AG & Co. KGaA
Lupin Pharmaceuticals Inc (Lupin Limited)
Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.)
Vifor Pharma Management Ltd. (CSL Limited)
Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic ketoacidosis, uncontrolled diabetes, and low parathyroid hormone levels. Medications for hyperphosphatemia, which tend to contain phosphate binders, help control the high levels of phosphate in the blood. Additionally, hyperphosphatemia drugs are effective at reducing phosphorus absorption through the gastrointestinal tract. They exchange an anion phosphate with an active cation, such as carbonate, acetate, oxyhydroxide, or citrate, to form a compound that is nonabsorbable and excreted.
Hyperphosphatemia Drugs Market Trends:
The rising prevalence of various chronic diseases, particularly end stage kidney disease (ESKD), across the globe is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the geriatric population that is susceptible to developing these ailments. In line with this, the increasing number of product launches due to the approval of novel drugs are positively impacting the market. Also, the introduction of strong pipeline drugs in numerous clinical trials is creating lucrative growth opportunities in the market. However, the growing side effects of hyperphosphatemia drugs, the rising stringency in regulations by the drug-governing bodies in several countries, and high production costs are restraining the market growth. On the contrary, extensive research and development (R&D) activities in drug manufacturing procedures are creating a positive outlook for the market. Apart from this, a significant increase in collaborations, partnerships and strategic merger and acquisition (M&As) by the key players to extend their geographical presence is also providing an impetus to the market. The market is further fueled by the shifting preference toward the adoption of non-phosphate binder drugs from the conventional phosphate binder drugs. Moreover, the increasing medical expenditure, along with continual technological improvements in the healthcare infrastructure facilities, are propelling the market. Some of the other factors contributing to the market include rapid urbanization, product premiumization, the rising trend of early disease diagnosis, considerable growth in the biotechnology industry and inflating disposable income levels.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global hyperphosphatemia drugs market, along with forecasts at the global, regional, and country level from 2025-2033. Our report has categorized the market based on product, dosage form, and distribution channel.
Product Insights:
Sevelamer
Calcium Based Phosphate Binders
Iron Based Phosphate Binders
Lanthanum Carbonate
Others
The report has provided a detailed breakup and analysis of the hyperphosphatemia drugs market based on the product. This includes sevelamer, calcium based phosphate binders, iron based phosphate binders, lanthanum carbonate, and others. According to the report, sevelamer represented the largest segment.
Dosage Form Insights:
Tablets
Syrups
Capsules
The report has provided a detailed breakup and analysis of the hyperphosphatemia drugs market based on the dosage form. This includes tablets, syrups, and capsules. According to the report, tablets represented the largest segment.
Distribution Channel Insights:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
A detailed breakup and analysis of the hyperphosphatemia drugs market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.
Regional Insights:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for hyperphosphatemia drugs. Some of the factors driving the North America hyperphosphatemia drugs market include the increasing number of product launches due to the approval of novel drugs, extensive research and development (R&D) activities conducted by key players, and the growing medical expenditure, along with continual technological improvements in healthcare infrastructure facilities.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global hyperphosphatemia drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Ardelyx Inc., Fresenius Medical Care AG & Co. KGaA, Lupin Pharmaceuticals Inc (Lupin Limited), Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.), Vifor Pharma Management Ltd. (CSL Limited), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
How has the global hyperphosphatemia drugs market performed so far and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global hyperphosphatemia drugs market?
What are the key regional markets?
Which countries represent the most attractive hyperphosphatemia drugs markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the dosage form?
What is the breakup of the market based on the distribution channel?
What is the competitive structure of the global hyperphosphatemia drugs market?
Who are the key players/companies in the global hyperphosphatemia drugs market?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hyperphosphatemia Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product
6.1 Sevelamer
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Calcium Based Phosphate Binders
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Iron Based Phosphate Binders
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Lanthanum Carbonate
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Dosage Form
7.1 Tablets
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Syrups
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Capsules
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Distribution Channel
8.1 Hospital Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Retail Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Online Pharmacies
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Ardelyx Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Fresenius Medical Care AG & Co. KGaA
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Lupin Pharmaceuticals Inc (Lupin Limited)
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.)
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Vifor Pharma Management Ltd. (CSL Limited)
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
*** 高リン血症治療薬の世界市場に関するよくある質問(FAQ) ***
・高リン血症治療薬の世界市場規模は？
→IMARC社は2024年の高リン血症治療薬の世界市場規模を44億米ドルと推定しています。
・高リン血症治療薬の世界市場予測は？
→IMARC社は2033年の高リン血症治療薬の世界市場規模を82億米ドルと予測しています。
・高リン血症治療薬市場の成長率は？
→IMARC社は高リン血症治療薬の世界市場が2025年～2033年に年平均6.7%成長すると展望しています。
・世界の高リン血症治療薬市場における主要プレイヤーは？
→「Ardelyx Inc., Fresenius Medical Care AG & Co. KGaA, Lupin Pharmaceuticals Inc (Lupin Limited), Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.), Vifor Pharma Management Ltd. (CSL Limited)など ...」を高リン血症治療薬市場のグローバル主要プレイヤーとして判断しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
